STAAR Surgical Company (NASDAQ:STAA) Receives $21.96 Consensus Target Price from Analysts

Shares of STAAR Surgical Company (NASDAQ:STAA) have earned a consensus rating of “Reduce” from the twelve ratings firms that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation and ten have assigned a hold recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $20.6786.

STAA has been the subject of several research analyst reports. BTIG Research reiterated a “neutral” rating on shares of STAAR Surgical in a research report on Tuesday, January 6th. Canaccord Genuity Group cut their price target on shares of STAAR Surgical from $30.75 to $22.00 and set a “hold” rating for the company in a report on Thursday. Morgan Stanley began coverage on shares of STAAR Surgical in a report on Friday. They set an “underweight” rating and a $13.00 price objective on the stock. Needham & Company LLC restated a “hold” rating on shares of STAAR Surgical in a research report on Tuesday, January 6th. Finally, Piper Sandler reiterated a “neutral” rating on shares of STAAR Surgical in a research report on Monday, October 27th.

Insider Buying and Selling at STAAR Surgical

In other news, major shareholder Broadwood Partners, L.P. purchased 797,486 shares of the business’s stock in a transaction dated Friday, November 21st. The stock was acquired at an average price of $27.86 per share, with a total value of $22,217,959.96. Following the purchase, the insider directly owned 15,019,491 shares of the company’s stock, valued at $418,443,019.26. This represents a 5.61% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders acquired a total of 1,934,138 shares of company stock valued at $50,485,791 in the last three months. Company insiders own 0.59% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Amalgamated Bank lifted its stake in STAAR Surgical by 3.6% in the 3rd quarter. Amalgamated Bank now owns 14,609 shares of the medical instruments supplier’s stock valued at $393,000 after buying an additional 514 shares in the last quarter. CWM LLC increased its position in STAAR Surgical by 74.1% during the second quarter. CWM LLC now owns 1,563 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 665 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of STAAR Surgical by 61.4% in the third quarter. GAMMA Investing LLC now owns 1,856 shares of the medical instruments supplier’s stock worth $50,000 after acquiring an additional 706 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in shares of STAAR Surgical by 7.8% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 12,711 shares of the medical instruments supplier’s stock valued at $213,000 after acquiring an additional 923 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its stake in shares of STAAR Surgical by 4.4% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 22,168 shares of the medical instruments supplier’s stock valued at $396,000 after acquiring an additional 934 shares during the last quarter. 96.70% of the stock is owned by hedge funds and other institutional investors.

STAAR Surgical Stock Performance

Shares of STAA stock opened at $20.97 on Friday. The stock has a 50 day simple moving average of $24.57 and a 200-day simple moving average of $24.66. The company has a market cap of $1.04 billion, a price-to-earnings ratio of -10.75 and a beta of 1.00. STAAR Surgical has a 12-month low of $13.50 and a 12-month high of $30.81.

Key Stories Impacting STAAR Surgical

Here are the key news stories impacting STAAR Surgical this week:

• Positive Sentiment: STAAR entered a cooperation agreement with Broadwood Partners to restructure the board and governance — a move investors often view as likely to push for operational improvements or strategic alternatives that can boost shareholder value. Read More.
• Positive Sentiment: A major shareholder purchased $606,044.25 of STAA stock, signaling insider/large-holder confidence and providing direct buying support to the share price. Read More.
• Neutral Sentiment: The board elected Neal C. Bradsher as chair and restructured board committees as part of the governance changes — a procedural but important step that clarifies leadership of the newly reshaped board. Read More.
• Negative Sentiment: CEO Thomas Farrell is exiting the company as part of the shareholder/cooperation developments, creating near-term leadership uncertainty that could weigh on operations and sentiment. Read More.
• Negative Sentiment: STAAR rejected/terminated a potential Alcon buyout, removing an acquisition premium and leaving uncertainty about future strategic transactions — a key reason some investors are cautious. Read More.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.